Non-Active SPMS Research in Phoenix: What the Monarch Study Listing Means

A research listing for secondary progressive multiple sclerosis can bring up a lot of questions. People may wonder what “non-active” means, whether a trial is available locally, how a randomized study works, and whether asking for information will change their regular care. Arizona Neuroscience Research (ANR) currently lists the Monarch study, ZB020-03-002, as a Phoenix-area research opportunity involving orelabrutinib for adults with non-active secondary progressive multiple sclerosis, often called SPMS.

Learning about a study is not the same as deciding to join it. A public listing gives a high-level overview. It cannot determine someone’s MS course, confirm eligibility, promise a local opening, or recommend a treatment. Those decisions require a conversation with qualified clinicians and the research team using the active version of the study protocol.

WHAT DOES SECONDARY PROGRESSIVE MS MEAN?
MS courses are described using clinical history, examination findings, imaging, and other information. In broad terms, secondary progressive MS refers to a course in which a person who previously had relapsing disease develops a pattern of gradual worsening over time. Symptoms and progression vary widely. Walking, balance, stiffness, fatigue, hand function, vision, cognition, bladder function, sensation, and mood can be affected differently for each person.

The words on a study listing are not a diagnosis. “Non-active” is a protocol term that may depend on defined criteria related to recent relapses, MRI activity, treatment history, timing, and other factors. No one should try to self-classify from one symptom or an internet checklist. A treating neurologist and the study team can explain how the current research protocol uses the term.

WHAT ANR CURRENTLY LISTS FOR MONARCH
ANR describes Monarch as a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating orelabrutinib in adults with non-active SPMS. The local listing identifies the study as ZB020-03-002 and directs visitors to ANR’s Current Studies and Volunteer Today pages for current local information. It also links to the ClinicalTrials.gov record NCT07299019 and to Zenas BioPharma’s pipeline information.

Those details describe the study design at a high level. They do not guarantee that a person will receive a study medicine, be assigned to a particular group, benefit, or qualify. They also do not tell a person whether the study is open at a specific Phoenix location on the day they inquire. Status, site capacity, and criteria can change.

HOW RANDOMIZATION, BLINDING, AND PLACEBO WORK
In a randomized study, a computer or other defined process assigns eligible participants to study groups according to the protocol. Randomization helps researchers make fair comparisons across groups. In a double-blind study, certain participants and study personnel may not know which assigned study option a participant receives during the blinded portion. A placebo is an inactive comparison designed to help researchers determine whether observed effects are connected with the study intervention.

These terms can sound personal, but they are scientific design tools. A person considering Monarch should ask the team to explain the current assignment process, what is known and not known during the study, what safety monitoring occurs, and what options exist at the end of participation. The research staff can explain the approved protocol; a treating clinician can discuss personal medical decisions.

WHAT SCREENING MAY INVOLVE
Screening is the step before enrollment when research staff review whether the protocol may fit a potential volunteer. It is also the volunteer’s chance to review information, ask questions, and decide whether the commitment makes sense. Screening can include a review of medical history, medications, prior treatments, MS course, examinations, laboratory work, imaging, questionnaires, or other assessments specified by the protocol. The site will explain the actual current requirements.

Bring an accurate list of prescriptions, over-the-counter products, vitamins, supplements, allergies, major diagnoses, surgeries, recent infections, hospital visits, and treating clinicians. Tell the team about changes in symptoms and any planned procedures or vaccinations. Do not stop, start, or change an MS medicine, steroid, supplement, or other treatment to try to meet a study criterion. Your safety and normal medical care come first.

QUESTIONS FOR A MONARCH RESEARCH CONVERSATION
Consider keeping these questions in a note on your phone:

• Is Monarch currently accepting screening inquiries at ANR?
• How does the current protocol define non-active SPMS?
• What information does the team need before deciding whether screening is appropriate?
• What does the screening period include, and where do visits take place?
• What is the study’s randomization and blinding process?
• What appointments, tests, questionnaires, or follow-up contact could be required?
• How will the study communicate with my usual MS neurologist?
• What should I do if symptoms change, I become ill, or another clinician prescribes a medicine?
• What happens if I decide not to enroll or do not qualify?

The point of these questions is clarity, not pressure. Participation is voluntary. You may ask for time to read the consent information, discuss it with people you trust, or decide that the study is not a good fit. Not qualifying for one protocol does not mean a person has failed or has no other care options.

KEEP RESEARCH AND ROUTINE CARE CONNECTED
Research involvement should not leave someone guessing who manages everyday MS concerns. Ask how the study team and your regular clinicians coordinate information, which team should receive updates about new symptoms, and how after-hours questions are handled. A study website or coordinator should never be your only plan for routine or urgent medical needs.

Call 911 or seek emergency care for sudden face droop, new one-sided weakness or numbness, trouble speaking, a sudden major vision change, chest pain, serious trouble breathing, loss of consciousness, or other possible emergency symptoms. New or rapidly worsening neurologic symptoms need clinical attention even if you are also considering a research study.

HOW TO CHECK LOCAL AVAILABILITY
The best source for local availability is ANR’s Current Studies page at https://azneuroscienceresearch.com/current-studies/. The Volunteer Today page at https://azneuroscienceresearch.com/volunteer-today/ provides current contact options. If you choose to inquire, use the study name Monarch and identifier ZB020-03-002 so the team knows which listing you mean.

The ClinicalTrials.gov record NCT07299019 is useful for public study-level background. Registry information is not a promise of Phoenix enrollment or eligibility. Ask ANR staff to confirm the status and the next appropriate step.

FREQUENTLY ASKED QUESTIONS

Does non-active SPMS mean I have no symptoms?
No. “Non-active” in a study listing has a specific research meaning. It does not mean someone has no symptoms, no disability, or no need for care.

Is orelabrutinib right for me?
A research listing cannot answer that. Orelabrutinib is being studied. Discuss treatment decisions with the clinicians who manage your MS.

Can I contact ANR just to ask questions?
Yes. Requesting information does not obligate you to enroll. The research team can explain current study status and the screening process.

TAKE THE NEXT INFORMED STEP
Adults in Arizona who want to learn more about the Monarch listing can review ANR’s Current Studies page, use Volunteer Today for current contact options, and prepare a medication list and questions. Keep your regular MS care team involved and take time to understand the consent information before making any decision.

Educational disclaimer: This article is general education only. It is not medical advice, an eligibility decision, a treatment recommendation, or a guarantee of enrollment, study assignment, individual benefit, or outcome. Study status and protocol details can change. Speak with qualified healthcare professionals about personal medical questions and seek emergency care for urgent symptoms.

INFORMED CONSENT AND PERSONAL CHOICE
Before a person joins a research study, the team should provide informed-consent information in language they can understand. This process includes the study’s purpose, the procedures it may involve, potential risks and discomforts, expected commitments, alternatives, confidentiality practices, compensation or reimbursement information when applicable, and contacts for questions or concerns. Consent is a conversation rather than a single signature. It should leave room for questions, time to think, and a voluntary decision.

Ask the team to explain what would happen if you decide to withdraw after enrollment. The answer depends on the protocol and the point in the study, but staff should be able to describe the available options and any safety follow-up that may be recommended. Nobody should feel pressured to continue because they already attended a screening visit or completed paperwork.

HOW RESEARCH INFORMATION IS HANDLED
Research studies have rules for collecting, storing, reviewing, and sharing information. The consent document should describe what information is collected, who may have access, how records may be coded or de-identified, and whether the sponsor, monitors, institutional review boards, or regulators may review information. If you are comfortable moving forward with a conversation, ask how the team handles communication with your usual neurologist and how you can update contact details or health information.

It is also helpful to ask about reporting. The protocol will define what symptoms, emergency visits, medication changes, infections, hospital stays, or other events need to be reported to the study team and how quickly. Keep the site’s contact information available. For a medical emergency, use emergency services first rather than waiting for a research callback.

PLANNING FOR VISITS IN PHOENIX
A research study can be easier to evaluate when the practical details are on the table. Consider transportation, Phoenix heat, mobility needs, caregiving responsibilities, parking, work schedules, and whether a support person would be useful. Ask which visits must happen in person, whether any follow-up is remote, how long visits may take, and whether there are specific appointment windows. Do not assume that transportation, reimbursement, or remote visits are included; only the current study team can describe the local plan.

A simple study notebook can help. Record the study name, Monarch, the identifier ZB020-03-002, names of the people you speak with, dates of calls or appointments, instructions you receive, and questions that remain unanswered. Bring the notebook and medication list to every conversation. This organization supports clear communication without replacing the records kept by your clinical and research teams.

WHY RESEARCH TERMS DESERVE CAREFUL READING
The language on a research page is written to describe a defined question, not to predict an individual outcome. A Phase 3 trial is generally a later-stage research study with a specific protocol. “Randomized,” “double-blind,” and “placebo-controlled” describe methods used to limit bias and make group comparisons more reliable. They do not promise access to a particular intervention, improvement in symptoms, or a result that applies to every person.

That distinction is useful for any Arizona adult considering an MS study. Be interested, but stay cautious. Use the local listing to decide whether you want a conversation, then use the consent process and your healthcare team to decide what is appropriate for you. A well-informed choice can include enrollment, declining, or waiting for a different opportunity. Keep a copy of the current study information and contact the ANR team whenever a detail needs confirmation.

LOCAL NEXT STEP
Before contacting any research site, consider noting your diagnosis history, current medications, and the questions you want answered. This can make an introductory research conversation easier to follow.